Literature DB >> 20107101

Achromobacter xylosoxidans genomic characterization and correlation of randomly amplified polymorphic DNA profiles with relevant clinical features [corrected] of cystic fibrosis patients.

Annarita Magni1, Maria Trancassini, Paola Varesi, Valerio Iebba, Anna Curci, Claudia Pecoraro, Giuseppe Cimino, Serena Schippa, Serena Quattrucci.   

Abstract

Achromobacter xylosoxidans is an emerging pathogen increasingly being isolated from respiratory samples of cystic fibrosis (CF) patients. Its role and clinical significance in lung pathogenesis have not yet been clarified. The aim of the present study was to genetically characterize A. xylosoxidans strains isolated from CF patients by use of randomly amplified polymorphic DNA (RAPD) profiles and to look for a possible correlation between RAPD profiles and the patients' clinical features, such as their spirometry values, the presence of concomitant chronic bacterial flora at the time of isolation, and the persistent or intermittent presence of A. xylosoxidans strains. A set of 106 strains of A. xylosoxidans were typed by RAPD analysis, and their profiles were analyzed by agglomerative hierarchical classification (AHC) and associated with the patient characteristics mentioned above by factorial discriminant analysis (FDA). The overall results obtained in this study showed that (i) there is a marked genetic relationship between strains isolated from the same patients at different times, (ii) characteristic RAPD profiles are associated with different predicted classes for forced expiratory volume in 1 s (FEV1%), (iii) some characteristic RAPD profiles are associated with different concomitant chronic flora (CCF) profiles, and (iv) there is a significant division of RAPD profiles into "persistent strains" and "intermittent strains" of A. xylosoxidans. These findings seem to imply that the lung habitats found in CF patients are capable of shaping and selecting the colonizing bacterial flora, as seems to be the case for the A. xylosoxidans strains studied.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20107101      PMCID: PMC2849589          DOI: 10.1128/JCM.02060-09

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  23 in total

1.  Use of random amplified polymorphic DNA PCR to examine epidemiology of Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans from patients with cystic fibrosis.

Authors:  J W Krzewinski; C D Nguyen; J M Foster; J L Burns
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

2.  Ribosomal DNA-directed PCR for identification of Achromobacter (Alcaligenes) xylosoxidans recovered from sputum samples from cystic fibrosis patients.

Authors:  Lixia Liu; Tom Coenye; Jane L Burns; Paul W Whitby; Terrence L Stull; John J LiPuma
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

3.  Recurrent Achromobacter xylosoxidans bacteremia associated with persistent lymph node infection in a patient with hyper-immunoglobulin M syndrome.

Authors:  J H Weitkamp; Y W Tang; D W Haas; N K Midha; J E Crowe
Journal:  Clin Infect Dis       Date:  2000-11-06       Impact factor: 9.079

4.  Inflammation, infection, and pulmonary function in infants and young children with cystic fibrosis.

Authors:  Carolyn J Dakin; Andrew H Numa; He Wang; John R Morton; Calypso C Vertzyas; Richard L Henry
Journal:  Am J Respir Crit Care Med       Date:  2002-04-01       Impact factor: 21.405

Review 5.  Pulmonary infections in patients with cystic fibrosis.

Authors:  Sujatha Rajan; Lisa Saiman
Journal:  Semin Respir Infect       Date:  2002-03

6.  Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients.

Authors:  C R Hansen; T Pressler; K G Nielsen; P Ø Jensen; T Bjarnsholt; N Høiby
Journal:  J Cyst Fibros       Date:  2009-11-25       Impact factor: 5.482

Review 7.  Infection control in cystic fibrosis.

Authors:  Lisa Saiman; Jane Siegel
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

8.  Achromobacter xylosoxidans bacteremia: a 10-year analysis of 54 cases.

Authors:  J Gómez-Cerezo; I Suárez; J J Ríos; P Peña; M J García de Miguel; M de José; O Monteagudo; P Linares; A Barbado-Cano; J J Vázquez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-05-16       Impact factor: 3.267

9.  Alcaligenes infection in cystic fibrosis.

Authors:  Kenneth Tan; Steven P Conway; Keith G Brownlee; Christine Etherington; Daniel G Peckham
Journal:  Pediatr Pulmonol       Date:  2002-08

Review 10.  Lung infections associated with cystic fibrosis.

Authors:  Jeffrey B Lyczak; Carolyn L Cannon; Gerald B Pier
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132

View more
  7 in total

1.  Achromobacter xylosoxidans: characterization of strains in Brazilian cystic fibrosis patients.

Authors:  Rosana H V Pereira; Ana Paula Carvalho-Assef; Rodolpho M Albano; Tania W Folescu; Marcia C M F Jones; Robson S Leão; Elizabeth A Marques
Journal:  J Clin Microbiol       Date:  2011-08-17       Impact factor: 5.948

2.  Distribution of allelic variants of the chromosomal gene bla OXA-114-like in Achromobacter xylosoxidans clinical isolates.

Authors:  German Matías Traglia; Marisa Almuzara; Andrea Karina Merkier; Mariana Papalia; Laura Galanternik; Marcela Radice; Carlos Vay; Daniela Centrón; María Soledad Ramírez
Journal:  Curr Microbiol       Date:  2013-06-15       Impact factor: 2.188

3.  A case of meningitis due to Achromobacter xylosoxidans denitrificans 60 years after a cranial trauma.

Authors:  Patrick Manckoundia; Emmanuel Mazen; Alexis Saloff Coste; Sophie Somana; Sophie Marilier; Jean-Marie Duez; Agnès Camus; Laura Popitean; Julien Bador; Pierre Pfitzenmeyer
Journal:  Med Sci Monit       Date:  2011-06

4.  Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients.

Authors:  A Lambiase; M R Catania; M Del Pezzo; F Rossano; V Terlizzi; A Sepe; V Raia
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-01-31       Impact factor: 3.267

5.  Achromobacter xylosoxidans: an emerging pathogen carrying different elements involved in horizontal genetic transfer.

Authors:  German Matías Traglia; Marisa Almuzara; Andrea Karina Merkier; Christina Adams; Laura Galanternik; Carlos Vay; Daniela Centrón; María Soledad Ramírez
Journal:  Curr Microbiol       Date:  2012-08-28       Impact factor: 2.188

6.  Outbreak of Achromobacter xylosoxidans in an Italian Cystic fibrosis center: genome variability, biofilm production, antibiotic resistance, and motility in isolated strains.

Authors:  Maria Trancassini; Valerio Iebba; Nicoletta Citerà; Vanessa Tuccio; Annarita Magni; Paola Varesi; Riccardo V De Biase; Valentina Totino; Floriana Santangelo; Antonella Gagliardi; Serena Schippa
Journal:  Front Microbiol       Date:  2014-04-03       Impact factor: 5.640

Review 7.  Epidemic Achromobacter xylosoxidans strain among Belgian cystic fibrosis patients and review of literature.

Authors:  Piet Cools; Erwin Ho; Katleen Vranckx; Petra Schelstraete; Bettina Wurth; Hilde Franckx; Greet Ieven; Leen Van Simaey; Sabine Van Daele; Stijn Verhulst; Frans De Baets; Mario Vaneechoutte
Journal:  BMC Microbiol       Date:  2016-06-24       Impact factor: 3.605

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.